Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are just fine, thank you, now that the short person has made the bus ride to the local schoolhouse and the official mascots have settled into their snoozing positions. As for us, we are enjoying sunny skies and hot cups of stimulation — our flavor today is Jack Daniels, seriously. Meanwhile, here are some items of interest to move the day along. We hope you meet with much success and, as always, hope that you keep in touch …

Novartis (NVS) is closing a Sandoz facility in Broomfield, Colo., that makes generic drugs due to “double digit price erosion caused by customer consolidation and increased competition,” according to The Daily Camera. About 450 jobs will be lost as production is consolidated at its Wilson, N.C., manufacturing plant. The closure is expected to occur over about two years and the last phase is expected to be in the fourth quarter of 2019.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The EMEA list contains some of the drugs that are the subject of the “right to try” movement and the relative non improvement for most such drugs based on post approval data that we did not previously have.

  • If memory serves, failing though it is, Amneal noised in early 2016 that they were going to become the 5th largest generic house. This is indeed one way to do it or shall one say ‘to make an Impx’ as it were?

Comments are closed.